Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 18, 2017

View Archived Issues

Positive phase I/IIa data for jCell in retinitis pigmentosa

Izana Bioscience launches, obtains rights to Takeda's namilumab for ankylosing spondylitis

Myonexus Therapeutics secures financing to develop gene therapies for limb-girdle muscular dystrophy

Kyn Therapeutics completes series A financing

Vaccine to protect against H. influenzae type A licensed to InventVacc for manufacturing

New models of epileptic encephalopathy type 26 employ novel mutation

CHMP grants positive opinion to Cx601 for the treatment of perianal fistulas in Crohn's disease

Lysyl oxidase inhibitor from Pharmaxis shows promise in model of primary myelofibrosis

BioTheryX describes novel cereblon-binding small molecules

Jnana Therapeutics launches with series A financing to target metabolic genes

FDA lifts clinical hold on Alnylam Pharmaceuticals' fitusiran

Long non-coding RNA linked to lymph node metastasis in breast cancer

Pfizer launches Ibrance in Japan

EMA committee hands down positive opinion on burosumab for X-linked hypophosphatemia

Celgene and Cancer Research Technology enter drug discovery collaboration

Celltrion's trastuzumab biosimilar recommended for E.U. approval

EMA committee recommends approval of Ozempic for type 2 diabetes

Athenex begins IND process for oral eribulin

Phase Ib study of TG-02 in RAS-mutated colorectal cancer passes initial safety review

FDA grants priority review to Tagrisso sNDA in NSCLC

Horizon Discovery in agreement with Roche Diagnostics to support development of IHC assays

EMA committee recommends approval of Alkindi for pediatric adrenal insufficiency

Bristol-Myers Squibb initiates phase III study of BMS-986205 with nivolumab in advanced melanoma

Novel IRAK inhibitors discovered at Pharmacyclics

Chiesi patents neutrophil elastase inhibitors

DuoGel studied in phase I pharmacokinetic trial

AbbVie Sarl, Galapagos identify novel CFTR modulators

Ferring presents new angiotensin AT1 receptor antagonists

Bristol-Myers Squibb divulges novel Rho kinase 2 inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
US lawmakers demand that Kennedy be held accountable
BioWorld
As the systematic dismantling of the U.S. vaccine schedule escalates, the demands to hold Health and Human Services Secretary Robert Kennedy accountable are...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...